.Attributes Medication, Published online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec acquired FDA authorization after an unfavorable trial, which highlights the many intricacies and difficulties of drug progression in this setup.